Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management

Medicine (United States)

Volumn 67, Issue 4, 1988, Pages 248-269

  Maki, Dennis G ^a   Agger, William A ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CARBENICILLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; METICILLIN; NAFCILLIN; NITROFURANTOIN; OXACILLIN; PENICILLIN G; TETRACYCLINE; TICARCILLIN; VANCOMYCIN;

BACTEREMIA; CLINICAL ARTICLE; DIAGNOSIS; ENDOCARDITIS; ENTEROCOCCUS; HUMAN; PRIORITY JOURNAL; STREPTOCOCCUS GROUP D;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS; CASE REPORT; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; MALE; MIDDLE AGE; SEPTICEMIA; STREPTOCOCCAL INFECTIONS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023774629     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/00005792-198807000-00005     Document Type: Article

References (259)

1. Abrutyn E, Lincoln L, Gallagher M, Weinstein AJ. Cephalothin-gentamicin synergism in experimental enterococcal endocarditis. J Antimicrob Chemother 2: 153-158, 1978.
2. Agger WA, Maki DG. Efficacy of direct gram stain in differentiating staphylococci from streptococci in blood cultures positive for gram positive cocci. J Clin Microbiol 7: 111-113, 1978.
3. Alexander JB, Giacoia GP. Brief clinical and laboratory observations. Esirly onset nonenterococcal group D streptococcal infection in the newborn infant. J Pediatr 93: 489-490, 1978.
4. Andrews FW, Horder TJ. A study of the streptococci pathogenic in man. Lancet 2: 207, 775, 852, 1906.
5. Auekenthaler R, Wilson WR, Wright AJ, Washington JA II, Durack DT, Geraci JE. Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother 22: 447-448, 1982.
6. Barrali DT, Kenney PR, Slotman GJ, Burehard KW. Enterococcal bacteremia in surgical patients. Arch Surg 120: 5763, 1985.
7. Barry AL, Jones RN, Thornsberry C, Ayere LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother 26: 633-637, 1984.
8. Barry AL, Schoenknect FD, Shadomy S, Sherris JC, Thomsberry C, Washington JA, Kammer RB. In vitro activites of cefamandole and cephalothin against 1, 881 clinical isolates. Am J Clin Pathol 72: 858-860, 1979.
9. Bartlett JG, Louie TJ, Gorbach SL, Onderdonk AB. Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis. Rev Infect Dis 3: 535-541, 1981.
10. Bartlett JG, Onderdonk AB, Drude E, Goldstein C, Anderka M, Alpert S, McCormack WM. Quantitative bacteriology of the vaginal flora. J Infect Dis 163: 271-277, 1977.
11. Bauer AW, Kirby WMM, Sherris JC, Turek M. Antibiotic susceptibility testing by a standardized simple disk method. Am J Clin Pathol 45: 493-496, 1966.
12. Bavikatte K, Schreiner RL, Lemons JA, Gresham EL. Group D streptococcal septicemia in the neonate. Am J Dis Child 133: 493-496, 1979.
13. Beargie R, Lynd P, Tucker E, Duhring J. Perinatal infection and vaginal flora. Am J Obstet Gynecol 122: 31-33, 1975.
14. Beaty HN, Turek M, Petersdorf RG. Ampicillin in the treatment of enterococcal endocarditis. Ann Intern Med 65: 701-706, 1966.
15. Berk SL, Verghese A, Holtsclaw SA Smith JK. Enterococcal pneumonia. Occurrence in patients receiving broad-spectrum antibiotic regimens and enteral feeding. Am J Med 74: 153-154, 1983.
16. Bourque M, Quintiliani R, Tilton R. Synergism of cefazolin-gentamicin against enterococci. Antimicrob Agents Chemother 10: 157-163, 1976.
17. Ginsburg I. Streptococcus. In: Braude A, Davis C, Fierer J, eds. Infectious Disease and Medical Microbiology. Philadelphia: WB Saunders, pp. 250-253, 1985.
18. Brook I, Barrett CT Brinkman CR III, Martin WJ, Finegold SM. Aerobic and anaerobic bacterial flora of the maternal cervix and newborn gastric fluid and conjunctive: A prospective study. Pediatrics 63: 461-466, 1979.
19. Brook I, Randolph JG. Aerobic and anaerobic bacterial flora of bums in children. J Trauma 21: 313-318, 1981.
20. Brown AE. Neutropenia, fever, and infection. Am J Med 76: 421-428, 1984.
21. Bryan CS, Reynolds KL, Brown JJ. Mortality associated with enterococcal bacteremia. Surg Gynecol Obstet 160: 557-561, 1985.
22. Buchino JJ, Ciambarell E, Light I. Systemic Group D streptococcal infection in newborn infants. Am J Dis Child 133: 270-273 1979.
23. Bush L, Boscia J Kobasa W, Kayte D. LY,46032 treatment of experimental enterococcal endocarditis (abstract). In: Program and Abstracts of the 26th Interscience Conference for Antimicrobial Agents and Chemotherapy, 1987, New York. Washington, DC: American Society for Microbiology, p. 124, 1985.
24. Calderwood SA, Wennersten C, Moellering RC Jr, Kunz LJ, Krogstad DJ. Resistance to six aminoglycoside aminocyclitol antibiotics among enterococci: Prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother 12: 401-405, 1977.
25. Caprioli T, Zaccour F, Kasatiya SS. Phage typing scheme for group D streptococci isolated from human urogenital tract. J Clin Microbiol 2: 311-317, 1975.
26. Carrizosa J, Kaye D. Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med 88: 132-141, 1976.
27. Carrizosa J, Levison ME. Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother 20: 405-409, 1981.
28. Centers for Disease Control. Nosocomial infections surveillance, 1984. In: CDC Surveillance Summaries. MMWR 35 (ISS): 17SS-29SS, 1986.
29. Chandrasekar PH, Smith BR, LeFrock JL Carr B. Enterococcal superinfection and colonization with aztreonam therapy. Antimicrob Agents Chemother 26: 280-282, 1984.
30. Chempakanallore TT, Berk S, Eapen T. Enterococcal liver abscess associated with moxalactam therapy. Arch Intern Med 143: 1780-1781, 1983.
31. Clewell DB. Plasmids, drug resistance, and gene transfer in the genus Streptococcus. Microbiol Rev 45: 409-436, 1981.
32. Collins MD, Jones D, Farrow JAE, Kilpper-Balz R, Schleifer KH. Enterococcus avium nom. rev., comb, no.; E. casseliflavus nom. rev., comb, nov.; E. durans nom. rev., comb, nov.; E. gallinarum comb, nov.; and E. malodoratus sp. nov. International J Systematic Bacteriol 34: 220-23, 1984.
33. Courdron PE, Mayhall CG, Facklam RR, Spadora AC, Lamb VA, Lybrand MR, Dalton HP. Streptococcus faecium outbreak in a neonatal intensive care unit. J Clin Microbiol 20: 1044-1048, 1984.
34. Courvalin P, Carlier C, Collatz E. Plasmid-mediated resistance to amino-cyclitol antibiotics in group D streptococci. J Bacteriol 143: 541-551, 1980.
35. Courvalin PM, Shaw WV, Jacob AE. Plasmid-mediated mechanisms of resistance to aminoglycoeide-aminocyclitol antibiotics and to chloramphenicol in group D streptococci. Antimicrob Agents Chemother 13: 716-725, 1978.
36. Crider SR, Colby SD. Susceptibility of enterococci to trimethoprim and tnmethoprim sulfamethoxazo Ie. Antimicrob Agents Chemother 27: 71, 1985.
37. Deibel RH. The group D streptococci. Bacteriol Rev 28: 330-366, 1964.
38. Del Mar Lleo M, Canepari P, Cornaglia G, Fontana R, Satta G. Bacterio-static and bactericidal activities of β-lactams against Streptococcus (Enterococcus) faecium are associated with saturation of different penicillin-binding proteins. Antimicrob Agents Chemother 31: 1618-1626, 1987.
39. Dible JH. The enterococcus and the faecal streptococci: Their properties and relations. J Pathol 24: 3-34, 1978.
40. Dougherty SH. Role of enterococcus in intraabdominal sepsis. Am J Surg 148: 308-312, 1984.
41. Dougherty ST, Flohr AB, Simmons RL. Breakthrough enterococcal septicemia in surgical patients: 19 cases and a review of literature. Arch Surg 118: 232-238, 1983.
42. Drusano GL, Warren JW, Saah AJ, Caplan ES, Tenney JH, Hansen S, Granados J, Standiford HC, Miller EH Jr. A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet 154: 715-720, 1982.
43. Duff P, Keiser JF, Strong SL. A comparative study of two antibiotic regimens for the treatment of operative site infections. Am J Obstet Gynecol 142: 996-1003, 1982.
44. Duma RJ, Weinberg AN, Medrek TF, Kunz LJ. Streptococcal infections: A bacteriologic and clinical study of streptococcal bacteremia. Medicine 48: 87-127, 1969.
45. Durack DT, Starkebaum MK, Petersdorf RG. Chemotherapy of experimental streptococcal endocarditis. Prevention of enterococcal endocarditis. J Lab Clin Med 90: 171-179, 1977.
46. Editor's Column (Siegel JD, McCracken GH). Group D streptococcal infections. J Pediatr 93: 542-43, 1978.
47. El Solh N, Bouanchaud DH, Horodniceanu T, Roussel A, Chabbert YA. Molecular studies and possible relatedness between R plasmids from groups B and D streptococci. Antimicrob Agents Chemother 14: 19-23, 1978.
48. Eliopoulos GM, Färber BF, Murray BE, Wennersten C, Moellering RC Jr. Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother 25: 398-399, 1984.
49. Eliopoulos GM, Moellering RC Jr. Susceptibility of enterococci and Listeria monocytogenes to N-formidyl thienamycin alone and in combination with an aminoglycoside. Antimocrob Agents Chemother 19: 789-793, 1981.
50. Eliopoulos GM, Moellering RC Jr. Azlocillin, mezlocillin, and piperacillin: New broad-spectrum penicillins. Ann Intern Med 97: 755-760, 1982.
51. Eliopoulos GM, Wennersten C, Moellering RC, Jr. Resistance to β-lactam antibiotics in Streptococcus faecium, Antimicrob Agents Chemother 22: 295-301, 1982.
52. Evans AC, Chinn AL. The enterococci: With special reference to their association with human disease. J Bacteriol 54: 495-512, 1947.
53. Facklam RR. Recognition of Group D streptococcal species of human origin by biochemical and physiological tests. Appl Microbiol 23: 1131-1139, 1972.
54. Facklam RR. Comparison of several laboratory media for presumptive identification of enterococci and Group D streptococci. Appl Microbiol 26: 138-145, 1973.
55. Facklam RR. A review of the microbiological techniques for the isolation and identification of streptococci. Crit Rev Clin Lab Sci 287-317, 1976.
56. Facklam RR. Streptococci and enterococci In: Lennette EH, Balows A, Hausier WJ Jr, Truant JP, eds. Manual of Clinical Microbiology, 3rd ed, Washington, D.C.: American Society for Microbiology, Washington, pp. 88-110, 1980.
57. Facklam RR, Moody MD. Presumptive identification of Group D streptococci: The bile-esculin test. Appl Microbiol 20: 245-250, 1970.
58. Facklam RR, Padula JF, Thacker LG, Wortham EC, Sconyers BJ. Presumptive identification of Group A, B, and D streptococci. Appl Microbiol 27: 107-113, 1974.
59. Facklam RR, Thacker LG, Fox B, Eriquez L. Presumptive identification of streptococci with a new test system. J Clin Microbiol 15: 987-990, 1982.
60. Fass RJ, Ruiz DE, Gardner WG, Rotilie CA. Clindamycin and gentamicin. Arch Intern Med 137: 28-38, 1977.
61. Fass RJ, Wright CA. Comparative efficacies of mezlocillin and ampicillin alone or in combination with gentamicin in the treatment of Streptococcus faecalis endocarditis in rabbits. Antimicrob Agents Chemother 25: 408-410, 1984.
62. Feingold DS, Stagg NL, Kunz LJ. Extra-respiratory streptococcal infections: Importance of the various serologic groups. N Engl J Med 275: 357-361, 1966.
63. Fernandez-Guerrero M, Rouse MS, Henry NK, Geraci JE, Wilson WR. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother 31: 430-433, 1987.
64. Foley GE. Further observations on the occurrence of streptococci of groups other than A in human infection. N Engl J Med 237: 809-811, 1947.
65. Fontana R, Grossato A, Rosse L, Cheng YR, Satta G. Transition from resistance to hypersusceptibility to beta-lactam antibiotics associated with loss of a low-affinity penicillin-binding protein in a Streptococcus faecium mutant highly resistant to penicillin. Antimicrob Agents Chemother 28: 678-683, 1985.
66. Francioli P, Moreillon P, Glauser MP. Comparison of single doses of amoxicillin or of amoxicillin-gentamicin for the prevention of endocarditis caused by Streptococcus faecalis and by viri dans streptococci. J Infect Dis 152: 83-88, 1985.
67. Friedberg CK, Rosen KM, Bienstock PA. Vancomycin therapy for enterococcal and Streptococcus viridans endocarditis: Successful treatment of six patients. Arch Intern Med 122: 134-140, 1968.
68. Fukunaga FH. Gallbladder bacteriology, histology, and gallstones. Arch Surg 106: 169-171, 1973.
69. Gall SA, Kohan AP, Ayers OM, Hughes CE, Addison WA, Hill GB. Intravenous metronidazole or clindamycin with tobramycin for therapy of pelvic infections. Obstet Gynecol 57: 51-58, 1981.
70. Galpin JE, Chow AW, Bayer AS, Guze LB. Sepsis associated with decubitus ulcers. Am J Med 61: 346-350, 1976.
71. Garner JS, Bennett JV, Scheckler WE, Maki DG, Brachman PS. Surveillance of nosocomial infections In: Brachman PS, Eickhoff TE, eds. Proceedings of the International Conference on Nosocomial Infection. Center for Disease Control. Chicago: American Hospital Association, pp. 277-281, 1971.
72. Garrison RN, Fry DE, Berberich S, Polk HC. Enterococcal bacteremia: Clinical implications and determinants of death. Ann Surg 196: 43-47, 1982.
73. Georgopapadakou NH, Liu FY. Binding of β-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: Relation to antibacterial activity. Antimicrob Agents Chemother 18: 834-836, 1980.
74. Geraci JE, Martin WJ. Antibiotic therapy of bacterial endocarditis. Circulation 10: 173-194, 1954.
75. Gibbs RS, Blanco JD. Streptococcal infections in pregnancy. A study of 48 bacteremias. Am J Obstet Gynecol 140: 405-411, 1981.
76. Gibbs RS, Listwa HM, Dreskin RB. A pure enterococcal abscess after cesarean section. J Reprod Med 19: 17-20, 1977.
77. Gibbs RS, O'Dell TN, MacGregor RR, Schwarz RH, Morton H. Puerperal endometritis: A prospective microbiology study. Am J Obstet Gynecol 121: 919-925, 1975.
78. Giertz G. Enterococci in urinary tract infections: A bacteriological clinical study. Acta Chir Scand 94 (suppl 109): 1-168, 1946.
79. Gilbert DN, Eubanks N. Effect of pH and human serum on the susceptibility of group D streptococci (enterococci) to ampicillin in vitro. Antimicrob Agents Chemother 7: 387-395, 1975.
80. Ginsburg I. Mechanisms of cell and tissue injury induced by group A streptococci: Relation to poststreptococcal sequelae. J Infect Dis 126: 294-340, 1972.
81. Glew RH, Moellering RC Jr. Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob Agents Chemother 15: 87-92, 1979.
82. Goodhart GL. In vivo and in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 252: 748-779, 1984.
83. Gross PA, Harkavy LM, Barden GE, Flower MF. The epidemiology of nosocomial enterococcal urinary infection. Am J Med Sci 272: 75-81, 1976.
84. Gullberg RM. The enterococcus. Infect Control 7: 601-606, 1986.
85. Gutschik E, Jepsen OB, Mortensen I. Effect of combinations of penicillin and aminoglycosides on Streptococcus faecalis: A comparative study of seven aminoglycoside antibiotics. J Infect Dis 135: 832-836, 1977.
86. Guze PA, Kalmanson GM, Freedman LR, Ishida K, Guze LB. Antibiotic prophylaxis against streptomycin-resistant and susceptible Streptococcus faecalis endocarditis in rabbits. Antimicrob Agents Chemother 24: 514-517, 1983.
87. Hall RW, Bayer AS, Mayer WP, Pitchon HE, Yoshikawa TT, Guze LB. Infective endocarditis following human-to-human enterococcal transmission. Arch Intern Med 136: 1173-1174, 1976.
88. Haltiner RC, Migneault PC, Robertson RG. Incidence of thymidine-dependent enterococci detected on Mueller-Hinton agar with low thymidine content. Antimicrob Agents Chemother 18: 365-368, 1980.
89. Hamill, RJ, Maki DG. Endotoxic shock in the human caused by gram-negative bacilli. Etiology, clinical features, diagnosis, natural history, and prevention. In: Ptoctor R, ed. Handbook of Endotoxin: Clinical Aspects of Endotoxic Shock. Amsterdam: Elsevier Science Publishers, pp. 55-126, 1986.
90. Harding GKM, Buckwold FJ, Ronald AR, Marrie TJ, Brunton S, Koss JC, Gurwith MJ, Albritton WL. Prospective, randomized comparative study of clindamycin, chloramphenicol, and ticarcillin, each in combination with gentamicin in therapy for intra-abdominal and female genital tract sepsis. J Infect Dis 142: 384-393, 1980.
91. Harding GKM, Nicolle LE, Haase DA, Aoki FY, Stiver HG, Blanchard RJ, Kirkpatrick JR. Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections. Rev Infect Dis 6: S283-S292, 1984.
92. Henry NK, Wilson WR, Geraci JE. Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin. Antimicrob Agents Chemother 30: 725-728, 1986.
93. Hermans PE, Washington JA II., Polymicrobial bacteremia Ann Intern Med 73: 387-392, 1970.
94. Herzstein J, Ryan JL, Mangi RJ, Greco TP, Andriole VT. Optimal therapy for enterococcal endocarditis. Am J Med 76: 186-191, 1984.
95. Hindes RG, Willey SH, Murray BE, Eliopoulos RC, Moellering RC Jr. Ampicillin, gentamicin, and sulbactam against a β-Lactamase, highly gentamicin resistant Streptococcus faecalis in rat endocarditis (Abstract). In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986, New Orleans, LA. Washington, DC: American Society for Microbiology, p. 145, 1986.
96. Hoffmann SA, Moellering RC Jr. The enterococcus: "Putting the bug in our ears." Ann Intern Med 106: 757-771, 1987.
97. Hook EW III, Roberts RB, Sande MA. Antimicrobial therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother 8: 564-570, 1975.
98. Hoppes WL, Lemer PI. Nonenterococcal Group D streptococcal endocarditis caused by Streptococcus bovis. Ann Intern Med 81: 588-593, 1974.
99. Horodniceanu T, Bougueleret L, El-Solh N, Bieth G, Delbos F. High-level plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob Agents Chemother 16: 686-688, 1979.
100. Horstmeier C, Washington JA II. Microbiological study of streptococcal bacteremia. Appl Microbiol 26: 589-591, 1973.
101. Horvitz RA, von Graevenitz A. A clinical study of the role of enterococci as sole agents of wound and tissue infection. Yale J Biol Med 50: 391-395, 1977.
102. Hunter TH. Use of Streptomycin in the treatment of bacterial endocarditis. Am J Med 2: 436-442, 1947.
103. Ikeda DP, Barry AL, Anderson SG. Emergence of Streptococcus faecalis isolates with high-level resistance to multiple aminocyclitol aminoglycosides. Diagn Microbiol Infect Dis 2: 171-177, 1984.
104. Ingerman M, Pitsakis PG, Rosenberg A, Hessen MT, Abrutyn E, Murray BE, Levison ME. β-lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis 155: 1226-1232, 1987.
105. Jarrett F, Balish E, Moylan JA, Ellerbe S. Clinical experience with prophylactic antibiotic bowel suppression in bum patients. Surgery 83: 523-527, 1978.
106. Jawetz E, Gunnison JB, Coleman VR. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro. Science 111: 254-256, 1950.
107. Jawetz E, Sonne M. Pencillin-streptomycin treatment of enterococcal endocarditis. A re-evaluation. N Engl J Med 274: 710-715, 1966.
108. Jones RC, Theil ER, Johnson NA, Gollihar LN. Evaluation of antibiotic therapy following penetrating abdominal trauma. Ann Surg 201: 576-583, 1985.
109. Jones RN, Thomsberry C. Gram-positive superinfections: A consequence of model β-lactam chemotherapy. Antimicrob Newsletter 2: 17-24, 1985.
110. Jones WG, Barie PS, Yuri RW, Goodwin CW. Enterococcal bum sepsis: A highly lethal complication in severely burned patients. Am Surg 121: 649-653, 1986.
111. Kaye D. Enterococci: Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med 142: 2006-2009, 1982.
112. Kiani D, Quinn EL, Burch KH, Madhavan T, Saravolatz LD, Neblett TR. The increasing importance of polymicrobial bacteremia. JAMA 242: 1044-1047, 1979.
113. Kim MJ, Weiser M, Gottschall S, Randall EL. Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents. J Clin Microbiol 25: 787-790, 1987.
114. Klimek JJ, Ajemian E, Gracewski J, Klemas B, Rios I, Maderazo E, Quintiliani R. Enterococcal infections in a large community hospital with emphasis on bacteremia. Am J Infect Control 8: 58-61, 1980.
115. Koenig MG, Kaye D. Enterococcal Endocarditis: Report of nineteen cases with long-term follow-up data. N Engl J Med 264: 257-264, 1961.
116. Krogstad DJ, Korfhagen TR, Moellering RC Jr, Wennersten C, Swartz MN. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. J Clin Invest 61: 480-486, 1978.
117. Krogstad DJ, Moellering RC Jr. Genetic and physiologic determinants of the enterococcal response to antimicrobial synergism In: Schlesinger D, ed. Microbiology-1982. Washington, D.C.: American Society for Microbiology, pp. 398-399, 1982.
118. Krogstad DJ, Parquette AR. Defective killing of enterococci: A common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother 17: 965-968, 1980.
119. Lea AX, Sudan AW, Wood BA, Gentry LO. Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults. Antimicrob Agents Chemother 22: 32-35, 1982.
120. Leclercq R, Derlot E, Duval J, Courvalin P. Strains of Enterococcus faecium highly resistant to vancomycin and teichoplanin (Abstract). In: Program and Abstracts of 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987, New York. Washington, DC: American Society of Microbiology, p. 275, 1987.
121. Ledger WJ. Selection of antimicrobial agents for treatment of infections of the female genital tract. Rev Infect Dis 5: S98-S104, 1983.
122. Ledger WJ, Kriewall TJ, Sweet RL, Fekety FR. The use of parenteral clindamycin in the treatment of obstetric-gynecologic patients with severe infections. Obstet Gynecol 43: 490-496, 1974.
123. Ledger WJ, Norman M, Gee C, Lewis W. Bacteremia on an obstetric-gynecologic service. Am J Obstet Gynecol 121: 205-212, 1975.
124. Lincoln LJ, Weinstein AJ, Gallagher M, Abrutyn E. Penicillinase-resistant penicillins plus gentamicin in experimental enterococcal endocarditis. Antimicrob Agents Chemother 12: 484-489, 1977.
125. Luginbuhl LM, Rotbart HA, Facklam RA, Roe MH, Elliot JA. Neonatal Enterococcal Sepsis. Case Control Study and Description of an Outbreak. Pediatr Infect Dis 6: 1022-1030, 1987.
126. Maki DG. Infections associated with intravascular line. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Disease. New York: McGraw-Hill Book Company, pp. 309-363, 1982.
127. Maki DG. Nosocomial bacteremia: An epidemiologic overview. Am J Med 70: 719-732, 1981.
128. Maki DG, Agger WA. Enterococcal bacteremia-clinical features and risks of endocarditis (Abstract). In: Program and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1978, Atlanta, GA. Washington, DC: American Society for Microbiology, p. 282, 1978.
129. Maki DG, Weise CE, Sarafm HW. A semiquantitative culture method for identifying intravenous catheter-related infections. N Engl J Med 296: 1305-1309, 1977.
130. Malone DA, Wagner RA, Myers JP, Watanakunakorn C. Enterococcal bacteremia in two large community teaching hospitals. Am J Med 81: 601-606, 1986.
131. Mandeli GL, Kaye D, Levinson ME, Hook EW. Enterococcal endocarditis: An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med 125: 258-264, 1970.
132. Mandeli GL, Lindsey E, Hook EW. Synergism of vancomycin and streptomycin for enterococci. Am J Med Sci 259: 346-349, 1970.
133. Marier RL, Joyce N, Andriole VT. Synergism of oxacillin and gentamicin against enterococci. Antimicrob Agents Chemother 8: 571-573, 1975.
134. Maslow MJ, Levine JF, Pollock AA, Simberkoff MS, Rahal JJ Jr. Efficacy of a twelve-hour ceftriaxone regimen in the treatment of serious bacterial infections. Antimicrob Agents Chemother 22: 103-107, 1982.
135. Mathisen GE, Meyer RD, Thompson JM, Finegold SM. Clinical evaluation of moxalactam. Antimicrob Agents Chemother 21: 780-786, 1982.
136. Matsumoto JY, Wilson WR, Wright AJ, Geraci JE, Washington JAH. Synergy of penicillin and decreasing concentrations of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother 18: 944-947, 1980.
137. McCabe WA, Jackson GG. Gram-negative bacteremia. Etiology and ecology. Arch Intern Med 110: 847-855, 1962.
138. McGowan JE Jr, Barnes MW, Finland M. Bacteremia at Boston City Hospital: Occvurence and mortality during 12 selected years (1935-1972) with special reference to hospital-acquired cases. J Infect Dis 132: 316-335, 1975.
139. Mederski-Samoraj B, Murray BE. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis 147: 751-757, 1983.
140. Metchock B, Cooksey R, Hill B, Thomsberry C. Aminoglycoside-modifying enzymes (AMEs) among hospital isolates of high-level aminoglycoside (AG) resistant enterococci (Abstract). In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 1987.
141. Miller MH, El-Sokkary MA, Feinstein SA Lowy FD. Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans groups Emd enterococcal streptococci. Antimicrob Agents Chemother 30: 763-768, 1986.
142. Miyamura S, Ochiai H, Nitahara Y, Nakagawa Y, Terao M. Resistance mechanism of chloramphenicol in Streptococcus haemolyticus, Streptococcus pneumoniae and Streptococcus faecalis. Microbiol Immunol 21: 69-76, 1977.
143. Moellering RC Jr. Antimicrobial susceptibility of enterococci: In vitro studies of the action of antibiotics alone and in combination In: Bisno AL, ed. Treatment of Infective Endocarditis. New York: Grune & Stratton, pp. 81-96, 1981.
144. Moellering RC Jr. Enterococcal infections in patients treated with moxalactam. Rev Infect Dis 4: 708-711, 1982.
145. Moellering RC Jr. Infections due to group D streptococci. In: Holoway W, ed. Infectious Disease Reviews. Vol. 6. Mount Kisco, New York: Futura Publishing, pp. 1-17, 1981.
146. Moellering RC Jr. Streptococcus faecalis. In: Magilligan DJ Jr, Quinn EL, eds. Endocarditis: Medical and Surgical Management.
147. Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB. Species-specific resistance to antimicrobial synergism in Streptocoo cus faecium and Streptococcus faecalis. J. Infect Dis 140: 203-208, 1979.
148. Moellering RC Jr, Murray BE, Sehoenbaum SC, Adler J, Wennersten CB. A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis. J Infect Dis 141: 81-86, 1980.
149. Moellering RC Jr, Watson BK, Kunz LJ. Endocarditis due to group D streptococci: Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med 57: 239-250, 1974.
150. Moellering RC Jr, Weinberg AN. Studies on antibiotic synergism against enterococci: II. Effect of various antibiotics on the uptake of C-Iabeled streptomycin by enterococci. J Clin Invest 50: 2580-2584, 1971.
151. Moellering RC Jr, Wennersten C. Therapeutic potential of rifampin in enterococcal infections. Rev Infect Dis 5: 528-532, 1983.
152. Moellering RC Jr, Wennersten C, Medrek T, Weinberg AN. Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. In: Hobby G, ed., Antimicrobial Agents and Chemotherapy-1970. Washington, DC: American Society of Microbiology, pp. 355-360, 1971.
153. Moellering RC Jr, Wennersten C, Weinberg AN. Studies on antibiotic synergism against enterococci. J Lab Clin Med 77: 821-828, 1971.
154. Moellering RC Jr, Wennersten C, Weinberg AN. Synergy of penicillin and gentamicin against enterococci. J Infect Dis 124: 207-209, 1971.
155. Montif GRG, Clark PR, Shuster JJ, Baer H. Susceptibility of the anaerobic bacteria, Group D streptococci, Enterobacteriaceoe, and Pseudomonas to semisynthetic penicillins; carbenicillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother 14: 643-649, 1978.
156. Murillo J, Standiford HC, Holley HP, Tatem BA, Caplan ES. Prophylaxis against enterococcal endocarditis: Comparison of the aminoglycoside component of parenteral Emtimicrobial regimens. Antimicrob Agents Chemother 18: 448-453, 1980.
157. Murray BE, Church DA, Wanger A, Zscheck K, Levison ME, Interman MJ, Abrutyn E, Mederski-Samoraj B. Comparison of two β-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother 30: 861-864, 1986.
158. Murray BE, Mederski-Samaroj B. Transferable beta-lactamase: A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clm Invest 72: 1168-1171, 1983.
159. Murray BE, Tsao J, Panida J. Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides. Antimicrob Agents Chemother 23: 799-802, 1983.
160. Muytjens HL, Van Der Ros-Van der Repe J. Comparative activities of 13 β-lactam antibiotics. Antimicrob Agents Chemother 21: 925-934, 1982.
161. Najjar A, Murray BE. Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci. Antimicrob Agents Chemother 31: 808-810, 1987.
162. National Committee for Clinical Laboratory Standards, 1984. Performance Standards for Antimicrobial Disk Susceptibility Tests. Villanova, PA: National Committee for Laboratory Standards, 1984.
163. Nichols RL. Empiric antibiotic therapy for intraabdominal infections. Rev Infect Dis 5: 590-597, 1983.
164. Noble CJ. Carriage of group D streptococci in the human bowel. J Clin Pathol 31: 1182-1186, 1978.
165. O'Brien JT, Geiser EA. Infective endocarditis and echocardiography. Am Heart J 108: 386-394, 1984.
166. Oblinger MJ, Bowers JT, Sande MA, Mandeli GL. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections. Rev Infect Dis 4: 639-649, 1982.
167. Onderdonk AB, Bartlett J G, Louie T, Sullivan-Seigler N, Gorbach SL. Microbial synergy in experimental intra-abdominal abscess. Iiifect Immun 13: 22-26, 1976.
168. Parker M, Ball LC. Streptococci and aerococci associated with systemic infection in man. J Med Microbiol 9: 275-302, 1976.
169. Patterson JE, Masecar BL, Zervos MJ. Characterization and comparison of two penicillinase-producing strains of Streptococcus (Enterococcus) faecalis. Antimicrob Agents Chemother 32: 122-124, 1988.
170. Pepper K, Horaud T, Le Bouguenec C, de Cespédes G. Location of antibiotic resistance markers in clinical isolates of Enterococcus faecalis with similar antibiotypes. Antimicrob Agents Chemother 31: 1394-1402, 1987.
171. Pfaller MA, Niles AC, Murray PR. Evaluation of the Kirby-Bauer disc diffusion test as a screening test for high-level aminoglycoside resistance in enterococci. Am J Clin Pathol 82: 458-460, 1984.
172. Pfaller MA, Niles AC, Murray PR. In vitro antibacterial activity of cefpiramide. Antimierob Agents Chemother 25: 368-372, 1984.
173. Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Ann Intern Med 104: 619-631, 1986.
174. Qadri SMH, Flournoy DJ, Qadri SGM. Sodium chloride-esculin hydrolysis test for rapid identification of enterococci. J Clin Microbiol 25: 1107-1108, 1987.
175. Quintiliani R, Cunha BA, Klimek J, Maderazo EG. Bacteremia after manipulation of the urinary tract. The importance of pre-existing urinary tract disease and compromised host defenses. Postgrad Med J 54: 668-671, 1978.
176. Rantz LA. The serological and biological classification of hemolytic and nonhemolytic streptococci from human sources. J Infect Dis 71: 62-68, 1942.
177. Rantz LA, Kirby WMM. Enterococci infections: An evaluation of the importance of fecal streptococci and related organisms in the causation of human disease. Arch Intern Med 71: 516-528, 1943.
178. Ravreby WD, Bottone EJ, Keusch GT. Group D streptococcal bacteremia with emphasis on the incidence and presentation of infections due to Streptococcus bovis: N Engl J Med 298: 1400-1403, 1973.
179. Reiner NE, Gopalakrishna KV, Phillip IL. Enterococcal endocarditis in heroin addicts. JAMA 235: 1861-1863, 1976.
180. Reller LB. The serum bactericidal test. Rev Infect Dis 8: 803-808, 1986.
181. Roselle GA, Watanakunakom C. Polymicrobial bacteremia. JAMA 242: 2411-2413, 1979.
182. Ryan RW, Kwasnik I, Tilton RC. Methodological variation in antibiotic synergy tests against enterococci. J Clin Microbiol 13: 73-75, 1981.
183. Sabbaj J, Sutter VL, Finegold SM. Comparison of selective media for isolation of presumptive group D streptococci from human feces. Appl Microbiol 22: 1008-1111, 1971.
184. Sahm DF, Baker CN, Jones RN, Thomsberry C. Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins. J Clin Microbiol 18: 858-865, 1983.
185. Sahm DF, Torres C. Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis. J Clin Microbiol 26: 250-256, 1988.
186. Sahm DF, Torres C. High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J Clin Microbiol 26: 257-260, 1988.
187. Salzer W, Pegram PS Jr. McCall CE. Clinical evaluation of moxalactam: Evidence of decreased efficacy in gram-positive aerobic infections. Antimicrob Agents Chemother 23: 565-570, 1983.
188. Sande MA, Scheid WM. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med 92: 390-395, 1980.
189. Sanders C. Comparative activity of mezlocillin, penicillin, ampicillin, carbenicillin, and ticarcillin against gram-positive bacteria and Haemophilus influenzae. Antimicrob Agents Chemother 20: 843-846, 1981.
190. Savani DV, Perfect JR. Durack DT. Comparison of LY,46032, ampicillin + gentamicin and vancomycin in the treatment of enterococcal pyelonephritis and endocarditis in rabbits. (Abstract). In: Program and Abstracts of the Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987, New York. Washington, DC: American Societv for Microbiology, 1987, p. 125.
191. Saymen DG, Nathan P, Holder IA. Infected surface wound: An experimental model and a method for the quantitation of bacteria in infected tissues. Appl Microbiol 23: 509, 1972.
192. Schaberg DR, Zervos MJ. Interspecies and intergeneric gene exchange in gram-positive cocci. Antimicrob Agents Chemother 30: 817-822, 1986.
193. Schleifer KH, Kilpper-Balz R. Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov. Int J Systematic Bacteriol 34: 31-34, 1984.
194. Schoolmeester WL, Kelley JW, Sawyer CG. Multivalvular vegetations in a patient with cnterococcal endocarditis diagnosed by echocardiography. South Med J 71: 644-648, 1978.
195. Serra P, Brandimarte C, Martino P, Carlone S, Giunchi G. Synergistic treatment of enterococcal endocarditis: In vitro and in vivo studies. Arch Intern Med 137: 1562-1567, 1977.
196. Sherman JM. The enterococci and related streptococci. J Bacteriol 35: 81-93, 1938.
197. Shlaes DM, Levy J, Wolinksy E. Enterococcal bacteremia without endocarditis. Arch Intern Med 141: 578-581, 1981.
198. Simon HJ. Antimicrobial susceptibility of Group D hemolytic streptococci (enterococci). Am J Med Sci 253: 14-18, 1967.
199. Smith JA, Forward AD, Skidmore AG, Bell GA, Murphy JM. Metronidazole and tobramycin in intra-abdominal sepsis. Surg Gynecol Obstet 155: 235-237, 1982.
200. Smith JW, Southern PM Jr, Lehmann JD. Bacteremia in septic abortion: Complications and treatment. Obstet Gynecol 35: 704-708, 1970.
201. Smith RF, Dayton SL. Colonization of bums by Streptococcus faecalis related to contaminated porcine xenografts. Tex Rep Biol Med 31: 47-54, 1973.
202. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 78(suppl 5A): 89-91, 1985.
203. Soriano F, Greenwood D. Action and interaction of penicillin and gentamicin on enterococci. J Clin Pathol 32: 1174-1179, 1979.
204. Spengler RF, Greenough WB III, Stolley PD. A descriptive study of nosocomial bacteremias at The Johns Hopkins Hospital, 1968-1974. Johns Hopkins Medical Journal 142: 77-84, 1978.
205. Stafford WJ, Petch J, Radford DJ. Vegetations in infective endocarditis: Clinical relevance and diagnosis by cross sectional echocardiography. Br Heart J 53: 310-313, 1985.
206. Standiford HD, de Maine JB, Kirby WM. Antibiotic synergism of enterococci. Arch Intern Med 126: 255-259, 1970.
207. Stone HH, Strom PR, Fabian TC, Dunlop WE. Third-generation cephalosporins for polymicrobial surgical sepsis. Arch Surg 118: 193-200, 1983.
208. Stratton CW, Liu C, Ratner HB, Weeks LS. Bactericidal activity of daptomycin (LY,46032) compared with those of ciprofloxacin, vancomycin and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 31: 1014-1016, 1987.
209. Sullam PM, Tauber MG, Hackbarth CJ, Sande MA. TTierapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother 27: 135-136, 1985.
210. Sullivan NM, Sutter VL, Mims MM, Marsh VH, Finegold SM. Clinical aspects of bacteremia after manipulation of the genitourinary tract. J Infect Dis 127: 49-55, 1973.
211. Sweet RL. Imipenem/Cilastatin in the treatment of obstetric and gynecologic infections: A review of worldwide experience. Rev Infect Dis 7: S522, 1985.
212. Tally FP, Gorbach SL. Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis. Am J Med 78(suppl 6A): 145-152, 1985.
213. Tally FP, McGowan K, Kellum JM, Gorbach SL, O'Donnell TF. A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Am Surg 193: 318-323, 1981.
214. Tashjian JH, Coulam CB, Washington JA II. Vaginal flora in asymptomatic women. Mayo Clin Proc 51: 557-561, 1976.
215. Thadepalli H, Gorbach SL, Broido PW, Norsen J, Nyhus L. Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet 173: 270-276, 1973.
216. Thauvin C, Eliopoulos GM, Wennersten C, Moellering RC Jr. Antagonistic effect of penicillin-amikacin combinations against enterococci. Antimicrob Agents Chemother 28: 78-83, 1985.
217. Thomson KR, Nanda NC, Gramiak R. The reliability of echocardiography in the diagnosis of infective endocarditis. Radiology 125: 473-476, 1977.
218. Thornsberry C. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria. Am J Med 79: 14-20, 1985.
219. Tight RR. Ampicillin therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother 18: 307-310, 1980.
220. Toala P, McDonald A, Wilcox C, Finland M. Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci 258: 416-430, 1969.
221. Tofle RW, Solliday J, Crossley KB. Susceptibilities of enterococci to twelve antibiotics. Antimicrob Agents Chemother 25: 532-553, 1984.
222. Tomich PK, Damle SP, Clewell DB. Plasmid-related transmissibility and multiple drug resistance in Streptococcus faecalis subspzvmogenes strain DS16. Antimicrob Agents Chemother 15: 828-830, 1979.
223. Tompsett R, Berman W. Enterococcal endocarditis: Duration and mode of treatment. Trans Am Clin Assoc 89: 49-57, 1977.
224. Tompsett R, Pizette M. Enterococcal endocarditis: Lack of correlation between therapeutic results and antibiotic sensitivity tests. Arch Intern Med 109: 146-150, 1962.
225. Trexler Hessen M, Pitsakis PG, Levison ME. Therapy of experimental rat endocarditis due to a beta-lactamase, aminoglycoside-resistant Streptococcus faecalis (Abstract). In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986, New Orleans. Washington, DC: American Society for Microbiology, p. 145, 1986.
226. Watanakunakorn C. Penicillin combined with gentamicin or streptomycin: Synergism against enterococci. J Infect Dis 124: 581-586, 1971.
227. Watanakunakorn C. Streptococcus bovis endocarditis. Am J Med 56: 256-260, 1974.
228. Watanakunakom C, Bakie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrob Agents Chemother 4: 120-124, 1973.
229. Watanakunakorn C, Glotzbecker C. Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci. Antimicrob Agents Chemother 11: 88-91, 1977.
230. Watanakunakom C, Glotzbecker C. In vitro activity of sisomicin and netilmicin alone and in combination with nafcillin, oxacillin and methicillin against enterococci. Chemotherapy 24: 236-239, 1978.
231. Weemes JJ Jr, Simpson WA, Baddour LM, Dale JB. Prevalence, susceptibility, and phenotypic characteristics of multiply aminoglycoside resistant enterococci (Abstract). In: Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987, New York. Washington, DC; American Society for Microbiology, p. 228, 1986.
232. Weinstein AJ, Moellering RC Jr. Penicillin and gentamicin therapy for enterococcal infections. JAMA 223: 1030-1032, 1973.
233. Weinstein AJ, Moellering RC Jr. Studies of cephalothin: Aminoglycoside synergism against enterococci. Antimicrob Agents Chemother 7: 522-529, 1975.
234. Weinstein MP, Reller LB, Murphy JR. Lichtenstein KA. The clinical significance of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 5: 35-53, 1983.
235. Weinstein MP, Stratton CW, Ackley A, Hawley HB, Robinson PA, Risher BD, Alcid DV, Stephens DS, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med 78: 262, 1985.
236. Weinstein RA. Kabins SA. Strategies for prevention and control of multiple drug-resistant nosocomial infection. Am J Med 70: 449-454, 1981.
237. Weinstein WM, Onderdonk AB, Bartlett JG, Louie TJ, Gorbach, SL. Antimicrobial therapy of experimental intra-abdominal sepsis. J Infect Dis 132: 282-286, 1975.
238. Welkon CJ, Long SS, Gilligan PH. Effect of imipenem-cilastatin therapy on fecal flora. Antimicrob Agents Chemother 29: 741-743, 1986.
239. Wells LD, von Graevenitz A. Clinical significance of enterococci in blood cultures from adult patients. Infection 8: 147-151, 1980.
240. Westenfelder GO, Paterson PY, Reisberg BE, Carlson GM. Vancomycin-streptomycin synergism in enterococcal endocarditis. JAMA 223: 37-40, 1973.
241. Whiteside M, Moore J, Ratzan K. An investigation of enterococcal bacteremia. Am J Infect Control 11: 125-129, 1983.
242. Wieshing L. Disc sensitivity as a diagnostic aid in the identification of Group D enterococci. Am J Med Technol 38: 496-500, 1972.
243. Wilkowske CJ. Enterococcal endocarditis. Mayo Clin Proc 57: 101-105, 1982.
244. Wilkowske CJ, Facklom RR, Washington JA III, Geraci JE. Antibiotic synergism: Enhanced susceptibility of Group D streptococci to certain antibiotic combinations. In: Hobby G, ed. Antimicrobial Agents and Chemotherapy-1970. Washington, DC: American Society for Microbiology, pp. 195-200, 1971.
245. Willey SH, Hindes RG, Eliopoulos GM, Moellering RC Jr. Efficacy of ampicillin, clindamycin and gentamicin alone and in combination in the therapy of enterococcal intra-abdominal abscess (Abstract). In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986, New Orleans. Washington, DC: American Society of Microbiology, p. 197, 1986.
246. Williamson R, Calderwood SB, Moellering RC Jr, Tomasz A. Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol 129: 813-822, 1983.
247. Wilson WR, Wilkowske CJ, Wright AJH, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 100: 816-823, 1984.
248. Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 77: 442-450, 1984.
249. Gallis, HA. Streptococcus. In: Jeklik WK, Willett MP, Amos DB, eds. Zinsser Microbiology. 18th ed. New York: Appleton and Lang, pp. 472-473, 1984.
250. Young LS, Martin WJ, Meyer RD, Weinstein RJ, Anderson ÉT. Gram-negative rod bacteremia, microbiologic, immunologic, and therapeutic considerations. Ann Intern Med 86: 456-471, 1977.
251. Young VM, Morris MJ, Moody MR, Schinpff SC, Gerster JW, Wiemik PH. An analysis of Group D streptococci recovered from cancer patients. Infection 6: 98-104, 1978.
252. Zervos MJ, Dembinski S, Mikesell T, Schaberg DR. High-level resistance to gentamicin in Streptococcus faecalis: Risk factors and evidence for exogenous acquisition of infection. J Infect Dis 6: 1075-1083, 1986.
253. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. Ann Intern Med 106: 687-691, 1987.
254. Zervos MJ, Mikesell TS, Schaberg DR. Heterogeneity of plasmids determining high-level resistance to gentamicin in clinical isolates of Streptococcus faecalis. Antimicrob Agents Chemother 30: 78-81, 1986.
255. Zervos MJ, Patterson JE, Edberg S, Pierson C, Kauffman CA, Mikesell TS, Schaberg DR. Single-concentration broth microdilution test for detection of high-level aminoglycoside resistance in enterococci. J Clin Microbiol 25: 2443-2444, 1987.
256. Zervos MJ, Schaberg DR. Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother 28: 446-448, 1985.
257. Zimmermann RA, Moellering RC Jr. Weinberg AN. Enterococcal resistance to antibiotic synergism. In: Hobby G, ed. Antimicrobial Agents and Chemotherapy-1971. Washington. DC: American Society for Microbiology, pp. 517-521, 1972.
258. Zimmermann RA, Moellering RC Jr. Weinberg AN. Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol 105: 873-879, 1971.
259. Yu VL. Enterococcal superinfection and colonization after therapy with moxalactam. a new broad-spectrum antibiotic. Ann Intern Med 94: 784, 1981.